Fentanyl Scripts After FDA REMS Program: What Happened?
March 29, 2019
Only a transient decline in prescriptions for transmucosal immediate-release fentanyl (TIRF) medicines occurred after the FDA ordered a restricted distribution program, an analysis of Medicare Part D beneficiaries found. But the Risk Evaluation and Mitigation Strategy program was associated with a lasting decline in TIRF prescriptions for patients not previously tolerant of opioids, according to William Fleischman, M.D., MHS, of Hackensack Meridian Health in New Jersey, and colleagues, writing online in JAMA Network.
READ FULL ARTICLE ON MEDPAGE TODAY